COMPASS Pathways Plc - American

CMPS

Healthcare

$9.74+4.51%vs prev close

$2.25

$10.21

52W RangeNear 52W High

+3.99 (+69.39%)Past 1M

Price

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

3,171,752

Portfolio Weight

0.23%

in ETF 2.5%

Est. Value

$30M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Strong Buy

Buy

Hold

Analyst Targets

avg.

$21.43

vs Current ▲ +120.0% upside

Current$9.74

Low ~ High$8.00 ~ $70.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Jefferies

Buy

$18.00

+84.80%

$9.52

Upgrade

2026-05-04

HC Wainwright & Co.

Buy

$70.00

+618.69%

$8.44

Maintain

2026-04-28

B. Riley Securities

Buy

$17.00

+74.54%

$9.58

Upgrade

2026-04-24

BTIG

Buy

$14.00

+43.74%

$9.46

Maintain

2026-04-20

Canaccord Genuity

Buy

$18.00

+84.80%

$5.64

Maintain

2026-03-26

1 / 14

Avg Target

$21.43

vs Current ▲ +120.0% upside

Strong Buy

14 analysts

Strong Buy 3Buy 10Hold 1

Low $8.00

Current $9.74

High $70.00

Firm	Position	Target	Upside	Close	Action	Date
Jefferies	Buy	$18.00	+84.80%	$9.52	Upgrade	26.05.04
HC Wainwright & Co.	Buy	$70.00	+618.69%	$8.44	Maintain	26.04.28
B. Riley Securities	Buy	$17.00	+74.54%	$9.58	Upgrade	26.04.24
BTIG	Buy	$14.00	+43.74%	$9.46	Maintain	26.04.20
Canaccord Genuity	Buy	$18.00	+84.80%	$5.64	Maintain	26.03.26

1 / 14

Price Information

Previous Close$9.32

Open$9.45

Day Range$9.16 - $9.76

52-Week Range$2.25 - $10.21

1-Year Change149.20%

Trading Volume

Volume2,058,628

Avg Volume (3mo)4,402,275

Valuation

Market Cap1.3B

Book Value$-0.55

Shares Outstanding134,923,295

Financials

Revenue (TTM)-

Net Income-287,862,016

EPS$-3.08

EBITDA-175,074,000

Profitability

P/E Ratio-

P/B Ratio-17.71

Return on Equity (ROE)-565.28%

Return on Assets (ROA)-51.68%

Profit Margin0.00%

EV/EBITDA-6.21

Beta2.40

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)70.81

Company Overview

COMPASS Pathways is a biotechnology company developing COMP360, a psilocybin therapy, for mental health conditions like treatment-resistant depression, PTSD, and anorexia nervosa. Currently in Phase III and II clinical trials, the company aims to be a leader in innovative mental health treatments.

P/B

-17.71

Negative equity

ROE

-565.3%

Persistent loss

Beta

2.40

Extreme volatility

RSI(14)

70.8

Overbought

AI-generated summary. Not investment advice.